Project Details
Description
ABSTRACT Premature infants with pulmonary hypertension associated with bronchopulmonary dysplasia (BPD-PH) carry alarmingly high mortality rates, experience an unacceptably high burden of morbidities, and have few therapeutic options. To date, no therapeutic agents have been rigorously evaluated for prevention or treatment of BPD-PH in this population. The L-arginine precursor, L-citrulline, serves as a substrate that promotes endogenous nitric oxide (NO) production. L-citrulline has demonstrated bioavailability when administered enterally to human infants and possesses a well-established, favorable safety profile during long-term use in children with inborn errors of metabolism. Our team recently completed a first-in-human phase 0 pharmacokinetic (PK) study of enteral L-citrulline in premature neonates at high risk of developing BPD-PH. The goal of this R61/R33 proposal is to conduct a metric-driven, multi-site, multi-dose, blinded and placebo- controlled safety and pharmacodynamic (PD) study of enteral L-citrulline in premature infants at high risk for developing BPD-PH. The resulting data will inform the selection of an enteral L-citrulline dosing strategy to be evaluated in a future phase 3 randomized controlled efficacy trial. To establish safety and generate pharmacodynamic data we will evaluate the impact of three different L-citrulline dosing strategies on relevant safety endpoints, and measure plasma L-citrulline concentrations to develop a population pharmacokinetic (PK) model. Additionally, we will explore the effects of L-citrulline on clinical parameters that may reflect efficacy. The following specific aims are designed to achieve this goal: Specific Aim 1 (Primary): Establish the safety profile of enteral L-citrulline in premature infants at high risk of developing BPD-PH. Infants will be treated for 4 weeks, from 32 weeks through 36 weeks postmenstrual age (PMA), with one of three different enteral L-citrulline dosing strategies. Specific Aim 2 (Primary): Develop a PK/PD model that links L-citrulline exposure to the proportion of infants who achieve trough plasma citrulline concentrations in the target range of 50-80 µmol/L. Specific Aim 3 (Exploratory): Provide preliminary evidence of clinical efficacy by evaluating whether steady-state trough plasma L-citrulline concentrations are associated with improvements in important clinical endpoints that serve as surrogates for BPD-PH. This study has the potential to improve human health by advancing L-citrulline as a therapy to prevent and mitigate a devastating disease in an understudied, high-risk patient population. Establishing a safe and effective treatment for premature infants with BPD-PH will reduce the unacceptably high rates of mortality and both short- and long-term morbidity, while also alleviating the extensive healthcare burden experienced by families and the medical system.
| Status | Active |
|---|---|
| Effective start/end date | 15/09/26 → 31/08/27 |
Funding
- National Heart, Lung, and Blood Institute
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.